How should a patient with low C‑peptide levels be evaluated and managed?

Low C-Peptide: Evaluation and Management

A patient with low C-peptide levels requires immediate assessment of concurrent glucose levels to determine the clinical context—low C-peptide with hypoglycemia (<55 mg/dL) indicates non-insulin-mediated hypoglycemia or exogenous insulin use, while low C-peptide with hyperglycemia indicates absolute insulin deficiency requiring insulin therapy.

Critical First Step: Measure Concurrent Glucose

The interpretation of low C-peptide is fundamentally different depending on whether the patient is hypoglycemic or hyperglycemic. Never interpret C-peptide in isolation—always obtain a simultaneous glucose measurement 1.

Clinical Context 1: Low C-Peptide with Hypoglycemia

Diagnostic Thresholds During Hypoglycemia

When plasma glucose is <55 mg/dL (3.0 mmol/L), normal physiologic suppression produces 1:

• Insulin <3 µU/mL (18 pmol/L)
• C-peptide <0.6 ng/mL (0.2 nmol/L)
• Proinsulin <5.0 pmol/L

Interpretation Algorithm

If C-peptide <0.6 ng/mL AND insulin <3 µU/mL during documented hypoglycemia:

• This represents appropriate suppression
• Rules out endogenous hyperinsulinism (insulinoma, nesidioblastosis)
• Consider non-insulin causes: critical illness, hormone deficiencies, non-islet cell tumors, drugs 1
• Screen for oral hypoglycemic agents to exclude surreptitious use 1

If C-peptide <0.6 ng/mL BUT insulin >3 µU/mL during hypoglycemia:

• Indicates exogenous insulin administration (factitious hypoglycemia) 2
• Exception: Some insulin analogs (lispro, aspart, glargine) may not be detected by certain assays, causing falsely low insulin readings 2

Required Workup for Hypoglycemia with Low C-Peptide

During a documented hypoglycemic episode, obtain 1:

1. Plasma glucose (laboratory-measured, not point-of-care)
2. Insulin
3. C-peptide
4. Proinsulin
5. β-hydroxybutyrate
6. Screen for oral hypoglycemic agents (sulfonylureas, meglitinides)
7. Insulin antibodies (can be measured later, not necessarily during hypoglycemia)
8. IV glucagon 1.0 mg with glucose measurements at 10,20,30 minutes

Clinical Context 2: Low C-Peptide with Hyperglycemia

Diagnostic Thresholds for Diabetes Classification

C-peptide <0.4 nmol/L (<0.12 ng/mL) with hyperglycemia indicates absolute insulin deficiency 3:

• Diagnostic of checkpoint inhibitor-associated diabetes mellitus (CIADM) in patients on immunotherapy
• Consistent with type 1 diabetes at any stage
• Requires insulin therapy

C-peptide <0.2 nmol/L (<0.06 ng/mL) strongly suggests type 1 diabetes 4, 5:

• The 2025 ADA guidelines use this threshold for type 1 diabetes classification
• Sensitivity 92.9% for distinguishing type 1 from type 2 diabetes 5

C-peptide 0.2-0.6 nmol/L (0.06-0.18 ng/mL) represents an intermediate zone 4:

• May indicate type 1 diabetes, MODY, or advanced type 2 diabetes
• Consider additional testing: diabetes autoantibodies (GAD, IA-2, ZnT8), genetic testing if MODY suspected
• Clinical context matters: age at diagnosis, BMI, family history, presence of ketoacidosis

Timing Considerations for C-Peptide Testing

Critical timing rules 4:

• Test within 5 hours of eating (random sample with concurrent glucose)
• If result >600 pmol/L (>1.8 ng/mL), timing doesn't matter
• If result <600 pmol/L (<1.8 ng/mL) and concurrent glucose <70 mg/dL or patient may have been fasting, repeat the test
• Very low levels (<80 pmol/L or <0.24 ng/mL) don't need repeating
• Do NOT test within 2 weeks of diabetic ketoacidosis 4
• For insulin pump coverage requirements: measure fasting C-peptide when fasting glucose ≤220 mg/dL 6, 7

Management Based on C-Peptide Results

If C-Peptide <0.4 nmol/L with Hyperglycemia

Immediate insulin therapy is required 3:

• Manage as type 1 diabetes regardless of apparent etiology
• Multiple daily injections or insulin pump
• Carbohydrate counting and dose adjustment education
• Continuous glucose monitoring strongly recommended
• Screen for other autoimmune conditions if type 1 diabetes confirmed

If C-Peptide 0.4-0.6 nmol/L with Hyperglycemia

Individualized approach based on additional factors 3:

• Check diabetes autoantibodies (GAD65, IA-2, ZnT8, insulin antibodies)
• If antibody-positive: treat as type 1 diabetes with insulin
• If antibody-negative and age <35 with family history: consider MODY genetic testing
• If antibody-negative and older: may represent advanced type 2 diabetes or type 3c (pancreatic) diabetes
• For type 3c diabetes: check fecal elastase; if low, start pancreatic enzyme replacement (Creon 25,000 IU with meals, 10,000 IU with snacks) 3

Common Pitfalls to Avoid

1. Assay variability: C-peptide assays are not standardized across manufacturers—results can vary significantly 8. Use the same laboratory for serial measurements.

2. Hypoglycemia artifact: C-peptide can be falsely low if measured during hypoglycemia or severe hyperglycemia (glucose toxicity) 5. Always check concurrent glucose.

3. Renal insufficiency: C-peptide is renally cleared—levels may be elevated in kidney disease, making interpretation difficult 1, 2.

4. Post-prandial timing: Random C-peptide >600 pmol/L (>1.8 ng/mL) within 5 hours of eating effectively rules out severe insulin deficiency 4.

5. Insulin analog interference: Some insulin analogs aren't detected by standard insulin assays, potentially mimicking non-insulin hypoglycemia 2.

Clinical Significance of Persistently Low C-Peptide

Even very low but detectable C-peptide levels (>10 pmol/L) in established type 1 diabetes are clinically meaningful 9:

• Protection from microvascular complications (nephropathy, neuropathy, retinopathy)
• Better HbA1c control
• Reduced risk of severe hypoglycemia
• C-peptide continues to decline for decades after diagnosis, with faster decline in those diagnosed at younger ages

Bottom line: Low C-peptide always requires correlation with glucose levels and clinical context. In hypoglycemia, it helps distinguish insulin-mediated from non-insulin causes. In hyperglycemia, it identifies absolute insulin deficiency requiring insulin therapy and helps classify diabetes type for optimal management.